HER2-Positive Breast Cancer Pricing and Reimbursement.
By Tijana Ignjatovic, Lead Analyst
12 January 2015
I am a Lead Analyst for market access and strategy at Datamonitor Healthcare. My team covers a diverse range of topics r...
Read full bio
Despite their high prices, Kadcyla and Perjeta have experience fast uptake in the US, however their high price tags have constricted their uptake in European markets. Once biosimilar versions of Herceptin become available, payers are expected to use patient and physician incentives to drive biosimilar use in an effort to contain rising costs.
Our new HER2-Positive Breast Cancer Pricing and Reimbursement report looks through the market context, as well as delving into the US, Japan and five major EU markets pricing and reimbursement decisions with regards to HER2-positive breast cancer therapies.
How will our HER2-positive Breast Cancer Pricing and Reimbursement report benefit you?
- Recognise your market restrictions
Understand the factors which leave payers with limited options for the utilization management of high price therapies, Kadcyla and Perjeta in the US.
- Understand the influence of biosimilars
Identify the effect that the entry of cheaper biosimilars in oncology, in general, may have on branded manufacturers reimbursed prices and sales volume.
- Increase your chance of securing market access
Analyse how EU markets are restricting Kadcyla and Perjeta’s uptake and what Roche will need to do to combat this.
Key questions answered
- What incentives will payers use to boost the uptake of biosimilar Herceptin?
- Why are Kadcyla and Perjeta reimbursed in some EU markets, and rejected in others?
- What influence will oncology pathways have on the future uptake of HER2-positive breast cancer drugs in the US?